FOR HEALTHCARE PROFESSIONALS
Technical information, outcomes, and references for clinical practice.
Clinical outcomes, visual acuity measures and safety for professional assessment. Study findings are presented with their population and follow-up; the refund guarantee is distinct from clinical response.
View patient informationMore comfort reading a phone, a menu, or a book. Explore presbyopia drops and how Yolia Health TVT fits in: a combination of ophthalmic drops and personalized contact lenses.
We work toward better vision that transforms daily activities: reading, working, and connecting with others. Our development starts with TVT for presbyopia and explores new applications.
People worldwide with presbyopia, 2015 estimate.
Published clinical evidence
Improve near vision and reduce dependence on reading glasses.
People worldwide with myopia, estimate for 2020.
Development direction
Explore applications of the platform to myopia control.
Near-vision needs can also arise after refractive surgery.
Development direction
Explore personalized options for this patient group.
These figures describe global need, not people treated by Yolia or eligible for TVT. They must not be added together: conditions can overlap. Development directions are described in Yolia’s 2022 publication; they do not represent demonstrated clinical outcomes for those indications.
Population source: WHO, World report on vision, figure 2.1 · Yolia publication and development directions
Selected reading on TVT and its scientific context. Each entry distinguishes Yolia-specific evidence from optical, pharmacological or preclinical background.
Clinical report in a professional publication
Rinehart, Kenyon, Osio, Monroy y Grant · Presbyopia Physician · 1 diciembre 2022, pp. 37–39
Single-center study without a control group: 50 adults followed for six months after the seven-day regimen used in that study. Reports improved near vision. Funded by Yolia, with author relationships disclosed. TVT-specific evidence, rather than independent validation.
Randomized trial · children · 2 years
Cho y Cheung · IOVS · DOI 10.1167/iovs.12-10565
Found less mean axial elongation than single-vision spectacles. Five participants discontinued orthokeratology because of adverse events. Supports the value of optical intervention, but did not study TVT or presbyopia.
Randomized trial · children · 2 years
Choi y colaboradores · Journal of Clinical Medicine · DOI 10.3390/jcm12093210
In this study of the Breath-O-Correct lens, 71 children completed follow-up; axial elongation was lower with orthokeratology. Clinical safety measures were similar between groups except for thinner central corneas. Relevant to outcome and ocular-surface monitoring, rather than validation of TVT.
Clinical study · monovision · 7 days
Optometry and Vision Science · DOI 10.1097/OPX.0b013e318287328e
Studied refractive changes with lens wear in one eye: 16 enrolled and 13 completed. The effect partly regressed during the day. Provides context for corneal optical modification in presbyopia; monovision and short follow-up differ from binocular TVT.
Randomized trial · sub-Tenon administration · 42 eyes
International Journal of Ophthalmology · DOI 10.3980/j.issn.2222-3959.2012.03.27
Adding the enzyme to anesthetic improved satisfaction and reduced postoperative pain. A favorable precedent for a specific ophthalmic use. Route, indication and formulation differ from TVT drops; it does not establish their topical safety.
Preclinical research · tissue and animal models
Gouveia y colaboradores · Nature Communications · DOI 10.1038/s41467-019-09331-6
Investigates corneal environment modulation to support epithelial stem-cell maintenance. A promising experimental precedent under defined conditions, rather than evidence of clinical TVT safety in humans.
Institutional educational resource
National Eye Institute · actualización 4 septiembre 2025
Distinguishes presbyopia, myopia, hyperopia and astigmatism. Explains why individual diagnosis and assessment come first in a discussion of TVT.
Original educational content with references; these are not new scientific studies.
More comfortable near vision means reading messages, checking a menu and enjoying a book with fewer interruptions. TVT aims to reduce reliance on reading glasses through personalized treatment without surgery.
TVT combines customized contact lenses and eye drops in a protocol with professional assessment and follow-up. The 2017 clinical report described an average improvement in binocular uncorrected near vision maintained at six months among 46 patients with final-visit data, from 50 at baseline.
An analysis of binocular uncorrected near vision in the corrected dataset found that all 50 patients had some improvement at one or more follow-up visits; 49 of 50 gained more than one line at their best visit. This describes the best recorded response during follow-up, not a constant gain at every visit. At the final recorded visit (visit 7), 40 of 46 patients gained at least one line and 33 of 46 gained more than one line from baseline. One line equals 0.1 logMAR; more than one includes fractional gains and does not necessarily mean two full lines. Improved visual acuity and independence from reading glasses are different outcomes.
Yolia offers a guarantee of at least two lines of improvement in binocular uncorrected near vision: if that result is not achieved, Yolia refunds the full treatment cost. Before starting, ask the team for the guarantee terms, the vision test used and the assessment timing.
Drops such as VUITY (pilocarpine) and VIZZ (aceclidine) reduce pupil size to temporarily improve near vision. They are used daily as prescribed. The studies in the VIZZ label describe an effect studied through ten hours.
The drops were evaluated separately for safety. The 2007 human study, involving 30 participants and a placebo group using isotonic solution and lubricant, concluded that the drops were safe to instill on the ocular surface under the conditions studied. A preclinical study also reported no signs of irritation or corneal changes during its observation period.
Contact lens use requires specific care and professional follow-up. Following hygiene and wear instructions helps reduce its risks. A clinical document on combined treatment described transient mild irritation and redness; that record alone does not establish whether the drops, lenses or protocol adherence caused those findings.
Presbyopia drops also have side effects. VIZZ trials reported eye irritation (20%), dim vision (16%) and headache (13%); most were mild and transient. The VUITY label lists headache and conjunctival redness among the most common adverse reactions (more than 5%).
Both labels warn about blurred or dim vision and rare retinal tears or detachments associated with miotic use. Eye examination and professional guidance are essential when selecting an appropriate option.
The named drops have controlled clinical trials described in their official labels. The TVT evidence summarized here comes from internal clinical documentation and the public 2022 report linked in the library. These figures come from different studies with different outcomes and follow-up periods. They do not constitute a direct comparison of efficacy or safety between TVT and the drops.
Sources: Yolia six-month clinical report (2017), corrected UAA dataset and TVT clinical paper; official VIZZ and VUITY labels.